Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 DiabetesXuqing Zhang, Mark J. Macielag, Bin Zhu et al.|ACS Medicinal Chemistry Letters|2021Cited by 6
Optimization of physicochemical properties of pyridone-based EP3 receptor antagonistsXuqing Zhang, Mark J. Macielag, Lili Guo et al.|Bioorganic & Medicinal Chemistry Letters|2021Cited by 5
Therapeutic Potential of EP3 Receptor Antagonists for Treatment of Noninsulin Dependent Diabetes Mellitus across Multiple Preclinical ModelsMatthew M. Rankin, Lisa Norquay, Lili Guo et al.|Diabetes|2018Cited by 2
Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 AntagonistsBin Zhu, Mark J. Macielag, Xuqing Zhang et al.|ACS Medicinal Chemistry Letters|2021Cited by 2
Erratum to “Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists” [Bioorg. Med. Chem. Lett. 47 (2021) 128172]Xuqing Zhang, Mark J. Macielag, Bin Zhu et al.|Bioorganic & Medicinal Chemistry Letters|2021Cited by 0